Inozyme Pharma Inc at Piper Sandler Healthcare Conference Transcript
Okay. Let's go ahead and get started with our next session. Thanks everybody for joining us. This is our 34th Annual Piper Sandler Healthcare Conference. Pleased to have with us our next presenter, which is Inozyme Pharma. The CEO, Axel Bolte is with me, next to me. I go through this every session, but just for everybody's benefit, this is a fireside chat, so by definition, very informal. So if anybody has any questions, please raise your hand. I'll make sure it gets asked and answered.
Axel, maybe before we launch into my questions, just for folks who might not necessarily understand the story or have familiarity with it, walk us through maybe sort of the elevator pitch, if you will, of Inozyme. And then I'll jump into my peppering you with questions.
That's great. Thank you, [Chris], and thanks a lot for inviting us. And we're obviously delighted to be here at the conference today. So Inozyme is a rare disease company. We're focused on these orders of mineralization.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |